HLA-A*02 has been shown to be overrepresented among patients with ovarian and PCa and to be associated with higher mortality rates [23], whereas its expression in lung adenocarcinoma and epithelial ovarian cancer patients has been associated with an unfavorable prognosis. Here, HLA-A is linked to posterior cortical atrophy.